about
Pharmacological evaluation of mild analgesics.Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeysPharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skinCharacterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptorsEndogenous cholinergic neurotransmission contributes to behavioral sensitization to morphineSphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNSThe effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacyDesign, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects.Role of CD38, a cyclic ADP-ribosylcyclase, in morphine antinociception and tolerance.Psychophysics of a nociceptive test in the mouse: ambient temperature as a key factor for variation.Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration.Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).beta-Endorphin: cross tolerance to and cross physical dependence on morphine.Involvement of phospholipid signal transduction pathways in morphine tolerance in miceSynergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivityDesign, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligandsMorphine efficacy is altered in conditional HIV-1 Tat transgenic mice.Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.Periaqueductal gray neuroplasticity following chronic morphine varies with age: role of oxidative stress.Analgesic activity of the naturally occurring heptapeptide [Met]enkephalin-Arg6-Phe7.Morphine Tolerance and Physical Dependence Are Altered in Conditional HIV-1 Tat Transgenic Mice.Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.Reversal of morphine analgesic tolerance by ethanol in the mouse.Codeine and its alternates for pain and cough relief. 2. Alternates for pain reliefMorphine tolerance in the mouse ileum and colonLigands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception.Contribution of acid sphingomyelinase in the periaqueductal gray region to morphine-induced analgesia in mice.Evidence for an important role of protein phosphatases in the mechanism of morphine tolerancePre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice.Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.Vitamin A active metabolite, all-trans retinoic acid, induces spinal cord sensitization. II. Effects after intrathecal administration.Some properties of WY 22811, a new analgesic compound.History and development of mixed opioid agonists, partial agonists and antagonists.Quantitative studies on the antagonism by naloxone of some narcotic and narcotic-antagonist analgesics.No evidence for the development of acute analgesic tolerance during and hyperalgesia after prolonged remifentanil administration in miceReversal of oxycodone and hydrocodone tolerance by diazepam.
P2860
Q24548008-D6BA4189-E111-4FF7-9406-6314575B22B1Q24597777-3CD1445E-7B8F-4C01-B1B6-7F52F277F852Q24681130-57637FB4-55D4-4901-88B4-69EF80708A1DQ28344581-0270AE45-45E2-4F18-AE8D-C4C52F423EA7Q28650541-B0E123AA-58F4-4ECE-AA11-A3692E32AAD2Q30435328-D155D54C-A0C4-4346-9970-0A0392E6BEB9Q33714922-F1F12331-4065-4E7E-A8F0-D28D7A8F0FB7Q33893723-299C4D3A-7718-42B5-A07D-14F4B2CB55D0Q34061067-C69B2FA0-DEFB-4AAD-9D39-380DD69D333BQ34128891-6CC62116-3644-4448-AF23-ED639AACB13CQ34281659-D6779E8E-0754-421A-BEAF-2F9B40C6B32EQ34401808-63BE5DC1-4214-4E21-80D1-5A7878F2AEDDQ34497517-3EC85AAF-632D-435A-A324-6530FBB3EEC2Q35037821-142A25B2-17F5-4B02-B800-84497C595160Q35041461-758D7198-1079-4738-8AB5-B133AECE3545Q35048705-D8CF9732-2830-4175-9B1A-92621400DE7CQ35216655-E82FC700-C8B4-4C9D-A4BD-812D9567695FQ35236118-2D8A5836-892C-4F9C-B46B-755591A4AFB4Q36109980-D126ABB6-EA10-49EB-BEEF-CA1F85756499Q36225640-C15F3022-402E-4807-8F3C-0AAA34D66141Q36358112-5E36D986-530D-43FA-99FC-B3A99D55686BQ36374150-7BFE17EE-122D-408C-83E0-95958B73B667Q36407454-88C88894-972B-4449-B253-FBFBD6EABDA2Q36432328-7952F96B-866C-4761-91E8-46E29B48A5B9Q36480105-0C50F4A5-B239-413C-AEE2-64872E127CB2Q36852601-C8F1C88E-51C2-4DAB-9D7B-82713C55F2F6Q36911126-4D7CD4E9-4081-47A4-B301-49598F9A8D32Q36952367-7A81992D-8AE0-47FF-9758-11848F5A47C9Q37010754-F1A6F27B-119F-4A09-9C3C-2295C46595B6Q37066909-28EE9795-70B3-4AE8-815F-216CF8393B21Q37077450-8D7AF299-6916-44DF-AE2B-C66EFCBDDBEEQ37172821-FA41FD4B-7411-4408-8148-6E8863EB5553Q37360643-0A1259CC-A25F-4F05-AA68-0C489D58A52FQ37444418-2A3D38EA-9EE6-47C2-AAA5-53A48523CA6AQ38961088-FF58BD3E-6651-499A-BB1A-B6132140D167Q39989672-D42CCDD5-FA24-4D0F-B844-E9FB75479AC4Q41076302-A55B1090-2010-4C3C-8527-E21E9FB5D34CQ41293479-5F72A08C-8847-4541-B509-37A91B70EFC0Q41786252-FDA55CE5-5F60-40DC-9D75-AE52D2D41E9EQ42003859-7A100D82-DCC9-424F-9FA0-52BC8660A3E3
P2860
description
1964 nî lūn-bûn
@nan
1964 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1964 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1964年の論文
@ja
1964年論文
@yue
1964年論文
@zh-hant
1964年論文
@zh-hk
1964年論文
@zh-mo
1964年論文
@zh-tw
1964年论文
@wuu
name
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@ast
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@en
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@nl
type
label
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@ast
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@en
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@nl
prefLabel
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@ast
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@en
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@nl
P1476
SOME NARCOTIC ANTAGONISTS IN THE BENZOMORPHAN SERIES
@en
P2093
P304
P407
P577
1964-02-01T00:00:00Z